PRAXIS PRECISION MEDICINES, INC. Operating Income
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Operating Income of -$96.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for the quarter ending 2026-06-30 was -$96.90M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for the quarter ending 2026-03-31 was -$105.86M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for the quarter ending 2025-12-31 was -$97.04M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for the quarter ending 2025-09-30 was -$78.36M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for fiscal 2025 was -$326.20M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for fiscal 2024 was -$200.16M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for fiscal 2023 was -$126.37M.
- PRAXIS PRECISION MEDICINES, INC. operating income (loss) for fiscal 2022 was -$214.99M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$96.90M 10-Q · filed 2026-08-06 | -$202.76M 10-Q · filed 2026-08-06 | -$299.81M derived: sum of 3 quarters · filed 2026-08-06 | -$378.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$105.86M 10-Q · filed 2026-05-07 | -$202.90M derived: sum of 2 quarters · filed 2026-05-07 | -$281.26M derived: sum of 3 quarters · filed 2026-05-07 | -$357.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$97.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$175.40M derived: sum of 2 quarters · filed 2026-02-19 | -$251.47M derived: sum of 3 quarters · filed 2026-08-06 | -$326.20M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$78.36M 10-Q · filed 2025-11-05 | -$154.43M derived: sum of 2 quarters · filed 2026-08-06 | -$229.15M 10-Q · filed 2025-11-05 | -$293.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$76.07M 10-Q · filed 2026-08-06 | -$150.79M 10-Q · filed 2026-08-06 | -$214.75M derived: sum of 3 quarters · filed 2026-08-06 | -$271.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$74.73M 10-Q · filed 2026-05-07 | -$138.68M derived: sum of 2 quarters · filed 2026-05-07 | -$195.52M derived: sum of 3 quarters · filed 2026-05-07 | -$233.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$63.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$120.79M derived: sum of 2 quarters · filed 2026-02-19 | -$158.28M derived: sum of 3 quarters · filed 2026-02-19 | -$200.16M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$56.84M 10-Q · filed 2025-11-05 | -$94.32M derived: sum of 2 quarters · filed 2025-11-05 | -$136.21M 10-Q · filed 2025-11-05 | -$164.01M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$37.49M 10-Q · filed 2025-08-04 | -$79.37M 10-Q · filed 2025-08-04 | -$107.18M derived: sum of 3 quarters · filed 2026-02-19 | -$132.70M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$41.89M 10-Q · filed 2025-05-02 | -$69.69M derived: sum of 2 quarters · filed 2026-02-19 | -$95.21M derived: sum of 3 quarters · filed 2026-02-19 | -$130.17M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$27.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$53.32M derived: sum of 2 quarters · filed 2026-02-19 | -$88.28M derived: sum of 3 quarters · filed 2026-02-19 | -$126.37M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$25.52M 10-Q · filed 2024-11-06 | -$60.48M derived: sum of 2 quarters · filed 2024-11-06 | -$98.57M 10-Q · filed 2024-11-06 | -$140.02M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$34.96M 10-Q · filed 2024-08-13 | -$73.05M 10-Q · filed 2024-08-13 | -$114.50M derived: sum of 3 quarters · filed 2024-08-13 | -$158.79M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$38.09M 10-Q · filed 2024-05-13 | -$79.54M derived: sum of 2 quarters · filed 2024-05-13 | -$123.83M derived: sum of 3 quarters · filed 2024-05-13 | -$184.23M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$41.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$85.74M derived: sum of 2 quarters · filed 2024-03-05 | -$146.14M derived: sum of 3 quarters · filed 2024-03-05 | -$214.99M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$44.29M 10-Q · filed 2023-11-07 | -$104.68M derived: sum of 2 quarters · filed 2023-11-07 | -$173.53M 10-Q · filed 2023-11-07 | -$232.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$60.39M 10-Q · filed 2023-08-09 | -$129.24M 10-Q · filed 2023-08-09 | -$187.90M derived: sum of 3 quarters · filed 2023-08-09 | -$232.67M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$68.85M 10-Q · filed 2023-05-11 | -$127.51M derived: sum of 2 quarters · filed 2023-05-11 | -$172.28M derived: sum of 3 quarters · filed 2023-05-11 | -$208.76M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$58.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$103.43M derived: sum of 2 quarters · filed 2023-02-07 | -$139.91M derived: sum of 3 quarters · filed 2023-02-07 | -$167.33M 10-K · filed 2023-02-07 |
| 2021-09-30 | -$44.77M 10-Q · filed 2022-11-09 | -$81.26M derived: sum of 2 quarters · filed 2022-11-09 | -$108.67M 10-Q · filed 2022-11-09 | -$134.39M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$36.48M 10-Q · filed 2022-08-08 | -$63.90M 10-Q · filed 2022-08-08 | -$89.61M derived: sum of 3 quarters · filed 2022-08-08 | -$105.83M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$27.42M 10-Q · filed 2022-05-09 | -$53.13M derived: sum of 2 quarters · filed 2022-05-09 | -$69.35M derived: sum of 3 quarters · filed 2022-05-09 | -$80.92M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$25.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$41.93M derived: sum of 2 quarters · filed 2022-02-28 | -$53.50M derived: sum of 3 quarters · filed 2022-02-28 | -$61.97M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$16.22M 10-Q · filed 2021-11-03 | -$27.79M derived: sum of 2 quarters · filed 2021-11-03 | -$36.26M 10-Q · filed 2021-11-03 | -$43.75M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$11.57M 10-Q · filed 2021-08-16 | -$20.04M 10-Q · filed 2021-08-16 | -$27.53M derived: sum of 3 quarters · filed 2021-08-16 | -$38.19M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$8.47M 10-Q · filed 2021-05-11 | -$15.96M derived: sum of 2 quarters · filed 2021-05-11 | -$26.62M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$18.15M derived: sum of 2 quarters · filed 2021-03-17 | -$35.79M 10-K · filed 2021-03-17 | |
| 2019-09-30 | -$10.65M 10-Q · filed 2020-11-23 | -$28.30M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |